Lighthouse Pharmaceuticals

Funding and NIH signals

• SEC Form D raise Raised $15.21M (Form D filed May 7, 2026). SEC Form D 0002133359-26-000001 (May 7, 2026)
  Evidence (1 event)

  • May 7, 2026 · SEC Form D 0002133359-26-000001
    Name of Issuer: Lighthouse Pharmaceuticals, Inc.; CIK: 2133359; Address: Novato, CA; Submission type: D; Filing date: 2026-05-07; Industry Group: Other; Date of First Sale: 2026-04-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15206800; Total Amount Sold: 15206800; Federal exemptions: 06b
• NIH award NIH awarded $12.59M (NIH grant 5R01AG088524-02, continuation, notice Aug 18, 2026). NIH RePORTER 5R01AG088524-02 (Aug 18, 2026)
  Evidence (1 event)

  • Aug 18, 2026 · NIH RePORTER 5R01AG088524-02
    Organization: LIGHTHOUSE PHARMACEUTICALS, INC.; City/State: Novato, CA; Project number: 5R01AG088524-02; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 12591952; Administering IC: National Institute on Aging; Project title: A Randomized, Double-Blind, Placebo-Controlled Study of LHP588 in Subjects with P. gingivalis-Positive Alzheimer's Disease; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals